U.S. Markets closed

Valeant Pharmaceuticals International, Inc. (VRX)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
14.14-0.25 (-1.74%)
At close: 4:00PM EDT

14.14 0.00 (0.00%)
After hours: 4:24PM EDT

People also watch
AGNGILDENDPFITTWTR

Valeant Pharmaceuticals International, Inc.

2150 St. Elzéar Boulevard West
Laval, QC H7L 4A8
Canada
514-744-6792
http://www.valeant.com

SectorHealthcare
IndustryDrug Delivery
Full Time Employees21,500

Key Executives

NameTitlePayExercisedAge
Mr. Joseph C. PapaChairman & CEO10.72MN/A62
Mr. Paul S. HerendeenExec. VP of Fin. & CFO10.75MN/A61
Ms. Christina M. AckermannExec. VP and Gen. Counsel2.04MN/A52
Mr. J. Michael PearsonConsultant11.97M60.51M58
Mr. Osama A. EldessoukyChief Accounting Officer, Sr. VP and Corp. ControllerN/AN/A45
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Valeant Pharmaceuticals International, Inc. operates as a pharmaceutical and medical device company worldwide. It operates in three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The company offers Lotemax gel for the treatment of inflammation and pain following ocular surgery; Ocuvite, a lutein eye vitamin and mineral supplement; PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus products; Biotrue multi-purpose solution for healthy contact lens wear; Artelac to treat dry eyes; Boston, a cleansing solution for gas permeable contact lenses; and Bedoyecta, a vitamin B complex. It also provides SofLens daily disposable contact lenses; ophthalmic surgical products; PureVision, a silicone hydrogel; Biotrue ONEday daily disposable contact lenses; Bausch + Lomb Ultra, a silicone hydrogel replacement contact lens; and medical device systems. In addition, the company offers Xifaxan for the treatment of irritable bowel syndrome; Provenge for the treatment of prostate cancer; Uceris to get ulcerative colitis under control; Arestin, a subgingival sustained-release antibiotic; Jublia for the treatment of onychomycosis; Solodyn for the treatment of acne; Elidel to treat skin conditions; and Glumetza tablets to enhance glycemic control. Further, it provides Wellbutrin XL for the treatment of major depressive disorder; Isuprel injections; Xenazine for the treatment of chorea; Nitropress for the reduction of blood pressure of patients in hypertensive crises; Cuprimine to treat Wilson's disease; Zegerid to treat certain stomach and esophagus problems; Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; and Latanoprost medicines to treat a type of glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. The company was founded in 1983 and is headquartered in Laval, Canada.

Corporate Governance

Valeant Pharmaceuticals International, Inc.’s ISS Governance QualityScore as of August 1, 2017 is 9. The pillar scores are Audit: 10; Board: 2; Shareholder Rights: 4; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.